Exavir_Logo_TransparentBackground.png
Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120
09 juin 2022 07h00 HE | Exavir Therapeutics
Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...
PB Logo (1).png
Pardes Biosciences to Present at Jefferies Global Healthcare Conference
01 juin 2022 08h30 HE | Pardes Biosciences, Inc
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Logo
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
23 mai 2022 07h00 HE | Exavir Therapeutics
NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...
PB Logo (1).png
Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
10 mai 2022 16h01 HE | Pardes Biosciences, Inc
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
PB Logo (1).png
Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
29 mars 2022 16h05 HE | Pardes Biosciences, Inc
CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
PB Logo (1).png
Pardes Biosciences to Present at the International Conference On Antiviral Research 2022
21 mars 2022 07h00 HE | Pardes Biosciences, Inc
CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
Logo.png
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344
10 mars 2022 08h00 HE | Cocrystal Pharma, Inc.
BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy...
PB Logo (1).png
Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mars 2022 16h30 HE | Pardes Biosciences, Inc
CARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
PB Logo (1).png
Pardes Biosciences to Present at Cowen Healthcare Conference
03 mars 2022 07h00 HE | Pardes Biosciences, Inc
CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
PB Logo (1).png
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
02 mars 2022 16h30 HE | Pardes Biosciences, Inc
Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be...